Sartorius Stedim Biotech S.A. Statistics
Share Statistics
Sartorius Stedim Biotech S.A. has 9.73B
shares outstanding. The number of shares has increased by -0.02%
in one year.
| Shares Outstanding | 9.73B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 300 |
| FTD / Avg. Volume | 186.34% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 1048.8 and the forward
PE ratio is null.
Sartorius Stedim Biotech S.A.'s PEG ratio is
-22.59.
| PE Ratio | 1048.8 |
| Forward PE | n/a |
| PS Ratio | 66.06 |
| Forward PS | n/a |
| PB Ratio | 46.07 |
| P/FCF Ratio | 386.38 |
| PEG Ratio | -22.59 |
Financial Ratio HistoryEnterprise Valuation
Sartorius Stedim Biotech S.A. has an Enterprise Value (EV) of 20.56B.
| EV / Sales | 7.39 |
| EV / EBITDA | 30.66 |
| EV / EBIT | 25.22 |
| EV / FCF | 43.25 |
Financial Position
The company has a current ratio of 1.85,
with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.85 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 4.28 |
| Debt / FCF | 6.04 |
| Interest Coverage | 2.48 |
Financial Efficiency
Return on Equity is 4.39% and Return on Invested Capital is 4.09%.
| Return on Equity | 4.39% |
| Return on Assets | 2.12% |
| Return on Invested Capital | 4.09% |
| Revenue Per Employee | $279,088.44 |
| Profits Per Employee | $17,578.56 |
| Employee Count | 9,961 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 2.3 |
Taxes
| Income Tax | 40.7M |
| Effective Tax Rate | 18.57% |
Stock Price Statistics
The stock price has increased by -1.99% in the
last 52 weeks. The beta is 0.98, so Sartorius Stedim Biotech S.A.'s
price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -1.99% |
| 50-Day Moving Average | 20.95 |
| 200-Day Moving Average | 20.12 |
| Relative Strength Index (RSI) | 55.63 |
| Average Volume (20 Days) | 161 |
Income Statement
In the last 12 months, Sartorius Stedim Biotech S.A. had revenue of 2.78B
and earned 175.1M
in profits. Earnings per share was 0.02.
| Revenue | 2.78B |
| Gross Profit | 1.21B |
| Operating Income | 370.6M |
| Net Income | 175.1M |
| EBITDA | 670.5M |
| EBIT | 368.8M |
| Earnings Per Share (EPS) | 0.02 |
Full Income StatementBalance Sheet
The company has 678.9M in cash and 2.87B in
debt, giving a net cash position of -2.19B.
| Cash & Cash Equivalents | 678.9M |
| Total Debt | 2.87B |
| Net Cash | -2.19B |
| Retained Earnings | 2.54B |
| Total Assets | 8.3B |
| Working Capital | 815.3M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 815.1M
and capital expenditures -339.8M, giving a free cash flow of 475.3M.
| Operating Cash Flow | 815.1M |
| Capital Expenditures | -339.8M |
| Free Cash Flow | 475.3M |
| FCF Per Share | 0.49 |
Full Cash Flow StatementMargins
Gross margin is 43.41%, with operating and profit margins of 13.33% and 6.3%.
| Gross Margin | 43.41% |
| Operating Margin | 13.33% |
| Pretax Margin | 7.88% |
| Profit Margin | 6.3% |
| EBITDA Margin | 24.12% |
| EBIT Margin | 13.33% |
| FCF Margin | 17.1% |
